In breast cancer, tumours that have evidence of HER2/neu gene amplification, or strong protein overexpression respond to treatment with the anti-HER2/neu monoclonal antibody Trastuzumab (Herceptin, Gnenetech Inc San Francisco, USA). Here, ERBB2 is linked to breast carcinoma.